Drug intelligence / Profile preview

SAR446422

Development stage: Unknown
Lead developer: Sanofi
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SAR446422 is a bispecific antibody developed by Sanofi for the treatment of inflammatory diseases. It is engineered to simultaneously target and modulate two critical T-cell costimulatory pathways: CD28 and OX40 (also known as CD134 or TNFRSF4). By dual-targeting these receptors, the molecule aims to suppress aberrant T-cell activation and restore immune homeostasis in autoimmune and inflammatory contexts. SAR446422 is currently undergoing Phase 1 clinical evaluation, including studies in healthy participants and patients with atopic dermatitis, to assess its safety, tolerability, and preliminary activity.

Targets

CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on SAR446422.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR446422.

Explore the full profile